Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene

Bone

Volumn 49, Issue 6, 2011, Pages 1178-1185

  Li, Chaoyang ^a   Ominsky, Michael S ^a   Tan, Hong Lin ^a   Barrero, Mauricio ^a   Niu, Qing Tian ^a   Asuncion, Franklin J ^a   Lee, Edward ^a   Liu, Min ^a   Simonet, William S ^a   Paszty, Chris ^a   Ke, Hua Zhu ^a  

^a AMGEN INC   (United States)

Author keywords

Bone density; Bone histomorphometry; Bone strength; Fracture healing; Radiography; Sclerostin knockout

Indexed keywords

SCLEROSTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE REMODELING; BONE STRENGTH; CALLUS; CARTILAGE CELL; CELL COUNT; CONTROLLED STUDY; DENSITOMETRY; DISEASE COURSE; FEMUR FRACTURE; FRACTURE HEALING; GENOTYPE; HISTOLOGY; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST;

ANIMALS; BONE DENSITY; BONY CALLUS; FEMORAL FRACTURES; FEMUR; FRACTURE HEALING; GLYCOPROTEINS; MALE; MICE; MICE, KNOCKOUT; ORGAN SIZE; STAINING AND LABELING;

EID: 81355127666     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.08.012     Document Type: Article

References (20)

1. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
2. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
3. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39:91-97.
4. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23:860-869.
5. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J Bone Miner Res 2009, 24:1651-1661.
6. Chen Y., Whetstone H.C., Lin A.C., Nadesan P., Wei Q., Poon R., et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med 2007, 4:e249. [1216-29].
7. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:578-588.
8. Ominsky M., Vlasseros F., Jolette J., Smith S., Stouch B., Doellgast G., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25:948-959.
9. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26:19-26.
10. Ke H.Z., Xiang J.J., Li X., Simonet W.S., Paszty C., Li G. Inhibition of sclerostin by systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in mice and rats. Trans ORS 2009, 34:221.
11. Ominsky M.S., Li C.Y., Li X., Tan H.L., Lee E., Barrero M., et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res 2011, 26:1012-1021.
12. Agholme F., Li X., Isaksson H., Ke H.Z., Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010, 25:2412-2418.
13. Bonnarens F., Einhorn T.A. Production of a standard closed fracture in laboratory animal bone. J Orthop Res 1984, 2:97-101.
14. Gerstenfeld L.C., Wronski T.J., Hollinger J.O., Einhorn T.A. Application of histomorphometric methods to the study of bone repair. J Bone Miner Res 2005, 20:1715-1722.
15. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
16. Fleiss J.L. Statistical methods for rates and proportions 1981, John Wiley, New York. second ed.
17. Axelrad T.W., Kakar S., Einhorn T.A. New technologies for the enhancement of skeletal repair. Injury 2007, 38:S49-S62.
18. Bishop G.B., Einhorn T.A. Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int Orthop 2007, 31:721-727.
19. Aspenberg P., Genant H.K., Johansson T., Nino A.J., See K., Krohn K., et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010, 25:404-414.
20. Zuscik M., O'Keefe R.J. Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research 2008, 61-65. C.J. Rosen (Ed.).